Hurtado, Felipe K. http://orcid.org/0000-0002-5254-972X
de Braud, Filippo
De Castro Carpeño, Javier
de Miguel Luken, Maria Jose
Wang, Ding
Scott, Jeffrey
Lau, Yvonne Y.
McCulloch, Tracey
Mau-Sorensen, Morten http://orcid.org/0000-0003-2235-1250
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Received: 29 June 2020
Accepted: 6 September 2020
First Online: 4 January 2021
Compliance with ethical standards
:
: F.K.H., J.S., and T.M. are full-time employees and stockholders of Novartis. Y.Y.L. was a Novartis employee until study completion. F.d.B. reports personal fees from Roche, outside the submitted work. F.J.C.C. reports personal fees (advisory board) from Pfizer, from Hoffmann-La Roche, Takeda, Novartis, during the conduct of the study; personal fees (advisory board) from Bristol-Myers Squibb, Merck-Sharp & Dohme, outside the submitted work. Remaining authors have nothing to disclose.
: The study was designed and conducted in accordance with the ethical principles of the Declaration of Helsinki and the guidelines for Good Clinical Practice, with applicable local regulations. The study protocol and all amendments were reviewed by an independent ethics committee or institutional review board for each center.
: All patients provided written informed consent before screening.